Automated Cell Counter Market

Global Automated Cell Counter Market is valued at USD 5.98 Billion in 2021 and expected to reach USD 8.22 Billion by 2028 with a CAGR of 4.6% over the forecast period.

Global Automated Cell Counter Market: Global Size, Trends, Competitive, And Historical & Forecast Analysis, 2022-2029: Throughout the forecast years, the cell counting industry is anticipated to grow due to the increasing prevalence of chronic illnesses and blood-related illnesses, technological advancements in cell counter devices, and the developing biopharmaceutical and biomedical sectors.

Scope-

The technique for measuring cells in bioscience, particularly medical assessment and therapy, is cell counting. It is an important branch of cytometry with uses in both clinical treatment and academic studies. When seeding cells for future studies, determining immortalization or transformations, transfected or infection, or getting ready for cell-based testing, cell counts are crucial for keeping track of cell health including proliferative velocity.

Autonomous cell counters are electrical tools that can measure cells from a variety of sources, including viruses, plants, bacteria, animals, and people. The material is placed into an automatic counter and driven via a tiny tube whereas the automatic counter counts the number of cells that pass via the tube using optical as well as electrical resistivity detectors.

Automatic cell counters are employed in healthcare and scientific facilities to analyze blood or urine specimens to count the variety of cells existing or to evaluate the viability of a cultivated cell line for analysis. Automatic counters may be used for urine or blood analysis. The requirements for sample size, the amount and kinds of cells it can assess, data administration, and the ability to distinguish between living and dead cells are the primary features that differ among the many automatic cell counts.

Covid-19 Impact-

The COVID-19 outbreak has had a favourable effect on the cell counting industry since it allowed for the diagnosis of COVID-19 individuals' cytokine ratios, T-cell activity, and cell count. The rise in prolonged and pathogenic diseases, the advancement of improved treatments, the expanding use of computerized hematology analyzers as well as flow rates cytometry, investments in cell-based studies, and the expanding bioengineering as well as biopharmaceutical businesses are a few of the variables boosting the cell counting industry.

Key Players-

The major players defining the competitive terrain of this business sphere are -

• Bio-Rad Laboratories Inc.
• Abbott Laboratories
• Danaher
• Thermo Fisher Scientific Inc
• NanoEnTek
• Sysmex Corporation
• F. Hoffmann-La Roche Ltd
• Agilent Technologies Inc.
• Olympus Corporation
• PerkinElmer Inc
• others

Segmentation-

By Product:

• Flow Cytometers
• Fluorescence Image-based Cell Counter
• Coulter Counter

By Application:

• Microbial Cells
• Blood Cells
• Cell Lines

By End-use:

• Diagnostic Laboratories
• Hospitals
• Pharmaceutical & Biotechnology Companies
• Research Institutes

By Regional & Country Level:

• North America

  • U.S.
  • Canada

• Europe

  • U.K.
  • France
  • Germany
  • Italy

• Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia

• Latin America

  • Brazil
  • Mexico

• Middle East and Africa

  • GCC
  • Africa
  • Rest of Middle East and Africa

Key Trends-

Increasing Government initiatives and Rising Number of Cancer cases worldwide, are Some of the Major Factors Driving the Market Growth

A crucial stage in determining cell concentrations for mounting in cultures, determining cell vitality, and assessing the outcomes of cell isolation techniques is cell counting. The goal of cell counting is to provide a clear picture of a cell's health and pace of development.

In 2022, the National Cancer Institute projected that there would likely be 1,918,030 novel cancer instances and 609,360 cancer fatalities in the country, with lung cancer accounting for the majority of these deaths with an average of roughly 350 people dying per day. It is recommended to do a preliminary cell count before cell isolation; the results of this comparison may be used to evaluate cell recovery. Thus, increasing cancer cases will drive the market growth over the coming years.

Government initiatives promoting the development of cell treatments, in which cell counting is essential, are enhancing the market's chances for potential development. Considering sixteen of the leading 50 global life science institutions are located in Europe, the continent is the world leader in cell and gene therapy (CGT) studies. According to the study, as a component of the Horizon Europe project, the European Union will spend almost 7 billion euros on health research throughout 2021 and 2027.

Additionally, the President's Emergency Plan for AIDS Relief (PEPFAR) of the United States provided HIV testing to about 50 million people in Fiscal Year 2020 and supported lifesaving ART for around 18.2 million men, and women, including children.

Market Restraints-

High Equipment Costs, And High Technical Skill Are Some Factors Expected To Hinder Market Growth

The high cost of apparatus, technology, and procedures discourages people from spending funds on cell counting techniques for medical or scientific reasons. Additionally, in developing countries, outdated equipment and underdeveloped healthcare facilities are barriers to the expansion of automatic cell counting.

Additionally, the industry for computerized cell counting is being constrained by a lack of qualified professionals. Additionally, there is a severe shortage of qualified employees and physicians in the healthcare sector, which may eventually restrain market expansion.

Geographical Landscape-

North America is Expected to Capture a Major Share in the Global Automated Cell Counter Market

Geographically, North America is predicted to hold a major share worldwide market for automated cell counts. Strong industry growth is anticipated as a result of expanding investments in development, the FDA's authorization of a less restrictive route for technology, and rising laboratory demand.

Industry growth is anticipated to be fuelled by leading companies in the area who are making robust investments to diversify their offerings in the field.  For example, Thermo Fisher Scientific Inc., a global leader in providing scientific services, announced intentions to spend $59 million to considerably increase its laboratory facilities in Highland Heights, Kentucky. This will enable customers to provide patients with life-changing medications.

The modern facility offers biopharma clients top-notch laboratory solutions to speed up drug research. It combines centralized lab as well as biomarker activities. In order to support novel therapies, such as vaccinations and cell and gene treatment products, a large portion of the development entails increasing the company's sample handling and testing capabilities.

Asia Pacific Is Expected To Grow At A Considerable Pace Over The Forecast Period

During the predicted timeframe, Asia Pacific is anticipated to increase exponentially. This region's concentration on medical studies and biopharmaceutical businesses is expected to propel market growth in the region. In addition, the region's industry is primarily driven by the aging geriatric demographic, which is extremely sensitive to chronic ailments. A rise in the number of elderly individual medical tests performed each year has contributed to the growth in the use of these equipment.

News-

DeNovix Inc Launched two Specialized Nuclei Counting Applications That Can Distinguish Between Whole Cells And Detritus And Isolated Nuclei

On August 3^th, 2022; DeNovix Inc, the creator of the acclaimed CellDrop Automated Cell Counter, created two specialised nuclei counting applications that can distinguish between whole cells and detritus and isolated nuclei. The updated DeNovix EasyApps programme includes the new applications as a free download.

Sysmex America, Inc., gained FDA Approval To Add Remnant White Blood Cell Counts to its XN-10 Automated Hematology Analyzers with Blood Bank option

On June 15^th, 2022; Sysmex America, Inc., a premier diagnostic technologies firm that provides haematology, urinalysis, information technologies, including flow cytometry testing technology for optimum clinical facility productivity, gained FDA approval to add remnant white blood cell counts to its XN-10 Automated Hematology Analyzers with Blood Bank option.

The FDA has approved just one automated haematological analyzer for remnant WBC counts. The most recent analyzer offers remnant red blood cell (RBC), white blood cell counts, and platelet (PLT) component analysis in a specific sampling aspiration, increasing the speed, uniformity, and reliability of blood processing facilities.

Mindray Launched hematology analyzer series that includes both the complete blood count (CBC) as well as erythrocyte sedimentation velocity (ESR) assays

On March 14^th, 2022; The BC-700 Series, a ground-breaking hematology analyzer series that includes both the complete blood count (CBC) as well as erythrocyte sedimentation velocity (ESR) assays, was  introduced by Mindray, a major worldwide supplier of medical solutions. The two open vials versions BC-700/BC-720 and the two autoloader versions BC-760/BC-780 are part of a series that is intended to equip medium-volume labs with cutting-edge diagnostics technology used in premium goods.

Report Analysis	Details
Historical data	2016 - 2021
Forecast Period	2022 - 2029
Market Size in 2021:	USD 5.98 Billion
Base year considered	2021
Forecast Period CAGR %:	4.6%
Market Size Expected in 2028:	USD 8.22 Billion
Tables, Charts & Figures:	175
Pages	300
Companies	Bio-Rad Laboratories, Inc., Abbott Laboratories, Danaher, Thermo Fisher Scientific Inc, NanoEnTek, Sysmex Corporation, F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., Olympus Corporation, PerkinElmer, Inc, and others
Segments Covered	By Product, By End-use, By Application
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa